Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, ...

On June 17, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) reported positive topline data from its Phase 2 Explore-CKD trial of lorundrostat.

The Palworld: Tides of Terraria update introduced many foes, one of which is the final boss of Terraria, the Moon Lord.

Apart from the Eye of Cthulhu, there are other mobs that you can capture inside the Sealed Realm of Terraria dungeon. These include slimes that help you bounce higher and bats that will collect ...

The Tides of Terraria crossover is live in Palworld, and there's a new location you can reach to find Terraria-themed Pals.

2025 NBA Round 2 mock draft: Johni Broome, Ryan Kalkbrenner go early in second-round projection With one round down and one to go, we take one final stab at a mock draft with projections for the ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.

GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Alongside the Eye of Cthulhu, the Moon Lord—Terraria’s ultimate boss and arguably its greatest threat—makes its debut as a raid boss in Palworld, promising an unprecedented level of challenge. “Tides ...